On December 20, Gelonghui announced that Tianjin Lisheng Pharmaceutical (002393.SZ) has released its 2024 Stock-based Incentive Plan. This incentive plan intends to grant up to 7,210,000 restricted stocks to the incentive objects, accounting for approximately 2.80% of the company's total share capital of 257,942,988 shares. Among them, 5,770,000 restricted stocks will be granted initially, accounting for 80.03% of the total number of restricted stocks; about 1,440,000 restricted stocks are reserved, accounting for 19.97% of the total number of restricted stocks.

After the implementation of this incentive plan, the total number of symbol stocks involved in all effective stock incentive plans of the company will not exceed 10% of the company's total share capital at the time of the announcement of the draft of this incentive plan. The total number of stocks granted to any incentive object through the stock incentive plan during the entire effective period will not exceed 1% of the company's total share capital at the time of the announcement of the draft of this incentive plan.